Adjuvant Capital

2Exits tracked$2.3bnDisclosed value$1.5bnMedian price0Acquihires

Startups backed by Adjuvant Capital that were acquired: 2 exits so far, with the buyer, the price where disclosed and every source.

Photo: Rhoda Baer (Photographer) / Wikimedia Commons, Public domain

Healthtech & bio · Schlieren

Ipsen to buy Swiss biotech Memo Therapeutics for €200 million upfront plus milestones

The French drugmaker is paying for one asset: potravitug, a Phase II antibody against BK polyomavirus in kidney-transplant patients. Memo's discovery platform and other staff are being split off into a new company its shareholders keep.

Price$800mRaisedn/aLast stageSeries CBuyer typeCorporate

Latest in Adjuvant CapitalBothell · Healthtech & bioEli Lilly agrees to buy shingles vaccine developer Curevo for up to $1.5 billion$1bn+Series B26 May

All Adjuvant Capital exitsOpen tracker →

1 JulIpsen → Memo TherapeuticsSchlieren · Series C · raised n/a$800m$250m–1bn 26 MayEli Lilly → CurevoBothell · Series B · raised n/a$1.5bn$1bn+